Key TakeawaysAbbVie is focusing on early-stage assets and gene therapy for retinal diseases to address unmet needs in wet AMD and DR.The acquisition of ImmunoGen and Cerevel Therapeutics diversifies AbbVie’s oncology and neuroscience portfolios, enhancing growth potential.AbbVie aims to leverage its commercial and regulatory expertise to maximize the potential of new therapies, driving long-term growth.AbbVie […]
